Eli Lilly — Aug 5, 2026 release

In addition to updates to Revenue and Performance Margin guidance, EPS guidance has been adjusted to reflect an increase of $2.78 (at the midpoint of the range) due to strong underlying business growth, offset by $3.03 associated with the Q2 acquired IPR&D charges from recent business development activity: Prior Updated Revenue $82 to $85 billion $85 to $87 billion Performance Margin (1)(2) 47.0% to 48.5% 49.0% to 50.5% Tax Rate (1)(3) 18% to 19% unchanged Earnings per Share (1)(3)(4) $35.50 to $37.00 $35.50 to $36.50 (1) Lilly does not provide reconciliations of forward-looking non-GAAP measures to the most directly comparable GAAP measures because comparable GAAP measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for a reconciliation. In particular, Lilly cannot reasonably predict certain items including net gains and losses on equity securities, asset impairment, acquisition or divestiture-related items, or restructuring and other adjustments, without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on Lilly's reported results in accordance with GAAP. See Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited) table below for additional Non-GAAP information. (2) The company defines performance margin as gross margin less research and development and marketing, selling, and administrative expenses divided by revenue. (3) Guidance does not include acquired in-